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ongoing VB12 treatment. ConClusions: PPI and metformin use did not appear as 
determinants of VB12 status in GAU patients whereas calcium supplements seem 
promoting better VB12 status. Whether calcium has counteracting effect on PPIs and 
metformin should be further examined using adjusted-analyses in a larger sample.
PIH7
Adverse drug events In tHe elderly OccurrIng In emergency, 
InPAtIent, And OutPAtIent dePArtments In An AdmInIstrAtIve clAIms 
dAtAbAse
Brown J.D.1, Painter J.1, Li C.1, Hutchison L.C.2, Martin B.1
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objeCtives: Adverse drug events (ADE) in the elderly are important sequelae of 
drug treatment playing a role in non-adherence and increased hospitalizations 
and emergency visits. This study sought to describe the rate of ADEs in an elderly 
population and to compare the characteristics of those who experienced ADEs to 
those who did not. Methods: This study was a retrospective cross-sectional analy-
sis that used a 10% random sample of the IMS LifeLink Health Plans commercial 
claims data during the period January 1,2001 through December 31, 2009. Subjects 
had to be at least 65 years of age and have had at least one year of continuous 
medical coverage. ADEs were defined based on previously published schema using 
ICD-9-CM codes that mention drug therapy or “due to drug” or “drug induced”. 
ADEs occurring in hospitalizations, emergency department visits, and outpatient 
physician visits are reported. Demographics, comorbidity, and health resource 
use were compared between persons with one or more ADEs compared to those 
without an ADE. Results: 402,078 persons were eligible with 2.1% having at least 
one ADE. The ADE exposed group was older (77.5 vs 74.9, p< 0.001), included more 
females (59.4% vs 54.5%, p< 0.001), had higher CCI scores (2.27 vs 1.53, p< 0.001and 
incurred nearly three times the average health care cost per person ($9,386 vs $2,962, 
p< 0.001). The most common ADEs experienced were mental disorders (0.30%) and 
dermatitis (0.24%) with anticoagulants (0.15%) and chemotherapy (0.13%) being 
the most prevalent associated drug groups. Nearly half (48.8%) of ADEs occurred in 
ED departments. ConClusions: Approximately 2% of persons age 65 and older 
experienced at least one ADE. ADEs frequently required ED care underscoring the 
severity of many ADEs and the need to develop interventions that can reduce ADE 
occurences in the elderly.
PIH8
cOmPArIng tHe effect Of sequentIAl tHerAPy WItH trIPle drug 
tHerAPy fOr HelIcObActer PylOrI erAdIcAtIOn In cHIldren: A 
systemIc revIeW And metA-AnAlysIs
Sharma S.1, Lin P.1, Wu W.K.2
1St John’s University, Queens, NY, USA, 2St John’s University, Jamaca, NY, USA
objeCtives: Previous meta-analysis on adults confirmed the superiority of sequen-
tial therapy (ST) over standard triple drug therapy (STT) for Helicobacter pylori eradi-
cation. The evidence of demonstrating the efficacy of using ST is still lacking. The 
aim of this study was to conduct a systemic review and meta-analysis comparing 
the efficacy of ST versus STT for the treatment of Helicobacter pyloriinfection in 
children. Methods: We used the keywords such as “Helicobacter pylori”, “H. pylori”, 
“infection”,“sequential therapy”, “triple drug therapy” “children” and searched 
Cochrane library, PubMed and Google Scholar for all the relevant randomized con-
trolled trials (RCTs), comparing the efficacy of two treatments (ST: proton pump 
inhibitor (PPI) + 1 antibiotic for 5 days followed by PPI + 2 antibiotics for another 5 
days; STT: PPI + 2 antibiotics for 7-10 days). The eradication rates were abstracted 
from included RCTs and Review Manager was used to estimate the pooled risk 
ratio (RR). Results: Five full text studies were included in the meta-analysis. They 
were published from 2005 to 2013. Three out of the five studies were of good quality 
(Jadad score ≥ 3).The superiority of ST over STT on the effect of Helicobacter pylori 
eradication was demonstrated, RR 1.24 (95 % CI 1.14, 1.36). No heterogeneity (I2 = 0) 
and publication bias (funnel plot was symmetrical). In the subgroup analyses, ST 
remained superior to STT regardless of the length of the STT (7 days or 10 days) (RR 
1.24, RR 1.21) as well as the type of antibiotics used as a part of ST (metronidazole 
or tinidazole) (RR 1.24, RR 1.26). ConClusions: The study indicated sequential 
therapy is superior to standard triple drug therapy for the eradication of Helicobacter 
pylori infection in children. More large RCTs are warranted to further confirm the 
efficacy due to the limited number of published studies.
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objeCtives: To characterize the temporal course of psychoactive drug utilization 
in a cohort of newly diagnosed autistic individuals. Methods: A cohort was built 
using the provincial public health care insurance program (RAMQ) databases. Newly 
diagnosed subjects with ASD were selected (≥ 2 diagnoses (separate dates) with 
ICD-9 codes: 299.X, excluding 299.2) between January 1998 and December 2010. 
Cohort entry was the date of first diagnosis confirmed by the absence of ASD diag-
nosis in previous 5 years. Participants aged ≥ 26 years or those not covered by the 
RAMQ drug plan in the year preceding cohort entry were excluded. Demographic 
and clinical patient characteristics were assessed at cohort entry. Drug use profiles 
(anticonvulsants, antipsychotics, antidepressants, anxiolytics, ADHD drugs) were 
evaluated for 5 years of follow-up. Impact of age groups on drug use profiles and 
variations over time were analyzed using generalized estimating equations (GEE) 
methods. Results: A cohort of 2,989 subjects was identified (male: 80.2%; median 
age: 6 years). Prior to ASD diagnosis, 35.8% received at least 1 psychoactive drug. At 
1-year of follow-up, 44.9% of participants were receiving at least 1 psychoactive med-
objeCtives: Limited evidence exists on the risk of falls/fractures with use of 
anticholinergic medications in the elderly. This study examined the risk of falls/
fractures associated with anticholinergic medication use. Methods: A nested case-
control design was conducted using regional Medicare Advantage Plan database. The 
base population included individuals aged > 65 years, who survived during the entire 
study period (2009-2010), had at least one institutional and one outpatient claim in 
first 6 months (January-June 2009) and no event of falls/fractures during the first 6 
months (Base Period). Cases were identified as patients who experienced incident 
diagnosis of falls/fractures following the base period. For each case, 4 age and sex-
matched controls were selected using incidence density sampling (incidence den-
sity 1:4). The primary outcome was an event of incident falls/hip fracture, between 
July 1, 2009 and December 31, 2010. The primary exposure was prescription of any 
anticholinergic medication 30 days preceding the event date. Anticholinergic expo-
sure was defined based on the Anticholinergic Drug Scale (ADS). Conditional logistic 
regression model stratified on matched case-control sets was used, with exposure 
to anticholinergic levels 1, 2 or 3 as the independent variable, falls/fractures as 
the outcome variable and other covariates associated with the outcome. Results: 
The study sample consisted of 449 cases diagnosed with falls/fractures and 1,796 
controls. After adjusting for other covariates, anticholinergic use was not associ-
ated with a statistically significant risk of falls/fractures (Relative Risk, RR 1.03; 
95% CI, 0.82-1.31) compared to no use. The study findings remained consistent 
when high-level anticholinergic drugs (level 2/3) were considered (RR 1.19; 0.85-
1.65). ConClusions: Use of anticholinergic medications was not associated with 
a higher risk of falls/fractures compared to no use, among patients with no history 
of falls/fractures. Future studies are needed to address the role of dose and con-
comitant use of anticholinergics to evaluate falls risk in the elderly.
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objeCtives: Anticholinergic medications are frequently prescribed in the elderly, 
and have been associated with potential central and peripheral adverse events. 
The current study examined the risk of all-cause hospitalization associated with 
anticholinergic use in the elderly. Methods: The study used a case-control design 
nested within a cohort of elderly individuals enrolled in a regional Medicare 
Advantage Prescription Drug Plan. The base population consisted of individuals 
aged > 65 years, who survived during the entire study period, had at least one 
institutional and one outpatient claim in first 6 months (January-June 2009) and 
no event of hospitalization during the first 6 months (Base Period). Cases for the 
study experienced incident inpatient hospitalization anytime following the base 
period. For each case, 4 age- and sex-matched controls were selected using inci-
dence density sampling (incidence density 1:4). The primary outcome measure was 
all-cause inpatient hospitalization. Prescription of any anticholinergic medication 
30 days before the hospitalization date formed the primary exposure, and was 
defined using the Anticholinergic Drug Scale (ADS). Conditional logistic regression 
stratified on matched case-control sets was used to model the hospitalization risk, 
after controlling for additional risk factors predictive of the outcome. Results: 
There were 295 cases that experienced incident hospitalization, and 1,180 age and 
sex-matched controls. After controlling for other covariates, use of anticholinergic 
medications was not associated with a significantly higher risk of hospitalization 
(Relative Risk, RR 0.85; 95% CI, 0.62-1.17) compared to no use. The findings remained 
unchanged after considering higher level (Level 2/3) anticholinergic use (RR 0.97; 
0.61-1.54). ConClusions: The study found that anticholinergic medication use 
was not associated with a significantly higher risk of hospitalization compared to 
no use, among the elderly with no history of hospitalization. Future studies with 
diverse samples are required to address the role of dose and concomitant use of 
anticholinergic agents in the elderly.
PIH6
vItAmIn b12 stAtus In frAIl Older Adults AdmItted In A gerIAtrIc 
Assessment unIt: cAn tHe use Of certAIn drugs be determInAnt?
Presse N.1, Kergoat M.J.2, Perreault S.1
1Université de Montréal, Montréal, QC, Canada, 2Institut universitaire de gériatrie de Montréal, 
Montréal, QC, Canada
bACkgRound: Use of proton pump inhibitors (PPIs) and metformin have emerged 
as potential risk factors of vitamin B12 (VB12) deficiency. Conversely, calcium sup-
plements were shown to counteract the detrimental effect of metformin on VB12 
absorption. These drugs are commonly prescribed to frail older adults in whom, 
VB12 deficiency is prevalent and has serious consequences. objeCtives: To exam-
ine proportions of PPI, metformin, and calcium supplement users according to vita-
min B12 status in frail older adults upon their admission to a Geriatric Assessment 
Unit (GAU). Methods: This cross-sectional study was based on 172 medical chart 
reviews of patients discharged from the GAU between 2008 and 2012. VB12 status at 
admission was categorized as follows: ongoing treatment for VB12 deficiency, low 
(< 148pmol/L), low-normal (148-221pmol/L), and normal (> 221pmol/L) serum VB12 
concentration. Use of PPIs, metformin and calcium supplements was determined 
from the pharmacist report. Proportions of PPI, metformin, and calcium supplement 
users were compared between VB12 status categories using χ 42statistics. Results: 
Most patients were women (67%), ≥ 75 years old (78%), and community-living (90%). 
Serum VB12 concentration was low and low-normal in 19% and 25% of patients, 
respectively; 19% had ongoing VB12 treatment. Prevalence of PPI and metformin 
users was 47% and 17%, respectively; these proportions did not vary significantly 
according to VB12 status. The use of calcium supplements was also prevalent (56%). 
Interestingly, proportions of calcium supplement users was found to vary signifi-
cantly between categories of VB12 status (P< 0.001), being of 21%, 35% and 62% in 
those with low, low-normal and normal status, respectively, and of 54% in those 
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Questionnaire; completed by participants ages 40 – 80. After exclusion of persons 
with negative sample weights and missing data, the final sample was 3437. Chi-
square and ANOVA were used to make statistical comparisons and all analyses 
were weighted to account for the sampling design. Results: The prevalence of 
taste dysfunction was 5.3% (95% CI 4.6, 6.1). Taste dysfunction was higher in older 
adults compared to younger adults (6.9% and 4.2%, respectively, p < .01), and in 
those reporting problems with smell compared to those with no problem (21.2% and 
3.4%, respectively, p < .0001). Persons with taste dysfunction reported significantly 
more days of poor physical health (mean = 6.4, SE = 1.1) and mental health (mean 
= 6.2, SE = 1.1) than those without problems with taste mean = 3.9, SE = .24, p = .04; 
mean = 3.7, SE = 0.24, p = .03, respectively). ConClusions: Based on self-reported 
data, taste dysfunction affects 5% of the weighted sample. Discrepancies between 
reported prevalence from 1994 are likely due to differences in the operationaliza-
tion of taste dysfunction. The association of problems with taste and the increase 
in reported days of poor physical and mental health should be investigated further.
PIH14
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objeCtives: Drugs with anticholinergic properties are associated with central and 
peripheral adverse effects in the elderly. The purpose of this study was to deter-
mine the prevalence and predictors of inappropriate anticholinergic medication 
use among the elderly as per 2012 American Geriatrics Society (AGS) Beers’ crite-
ria. Methods: A retrospective cross-sectional study design was conducted using 
2009-2010 Medical Expenditure Panel Survey (MEPS). The study sample included 
individuals aged ≥ 65 years. Inappropriate anticholinergic drugs were identified 
using the MEPS prescription files. Weighted descriptive statistics were used to esti-
mate the prevalence of inappropriate anticholinergic medication use in elderly 
patients. Multivariable logistic regression within the conceptual framework of 
Anderson Behavioral Model was used to identify predictors associated with the 
use of inappropriate anticholinergic medications in the elderly. Results: Analysis 
of the 2009-2010 MEPS data revealed that an estimated 78.6 million members of 
the US population were elderly. (12.78%) It was estimated that 7.51 million (95% CI: 
6.64 to 8.38) of elderly individuals used potentially inappropriate anticholinergic 
medications, resulting in an overall prevalence of 9.56%. The most frequently used 
inappropriate anticholinergics were cyclobenzaprine (2.08%), promethazine (1.75%), 
amitriptyline (1.47%), hydroxyzine (0.95%), and dicyclomine (0.84%). Multivariable 
analyses revealed that female gender (OR: 1.37; 95% CI: 1.06-1.77), South region (OR: 
1.88; 95% CI: 1.25-2.84) and anxiety disorder (OR: 2.15; 95% CI: 1.57-2.94) increased 
the likelihood of receiving inappropriate anticholinergic medications; whereas age 
between 75 to 84 years (OR: 0.64; 95% CI: 0.49-0.85), age > = 85 years (OR: 0.52; 95% 
CI: 0.33-0.81) and > 15 years of education (OR: 0.54; 95% CI: 0.35-0.84) decreased the 
likelihood of receiving inappropriate anticholinergic medications. ConClusions: 
The study found that approximately one in ten elderly patients used inappropriate 
anticholinergic medications. Several predisposing and need factors were associ-
ated with the use of inappropriate anticholinergic medications. Efforts are needed 
to improve inappropriate prescribing practices to optimize medication use in the 
elderly.
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objeCtives: Health care risk epidemiology identifies medication error as the 
commonest cause of adverse effects on patients. Errors can occur at any phase of 
the medication process, so incidence rates should be estimated along with their 
clinical outcomes at each stage. The aim of this study was to assess and analyze 
the medication errors for determining their nature, types, incidence and clinical 
significance in an Indian setting. Methods: This prospective observational study 
was conducted in 3 medical wards of a public teaching hospital. All the information 
was collected in a standard data collection form. Medication errors were identified 
and analyzed from patients’ records using Current Index of Medical Sciences (CIMS) 
and Micromedex Drug-Reax database. Results: Of the 450 studied, 87 patients 
were found to have 113 medication errors. The 3 most common errors were drug 
interactions followed by inappropriate frequency and overdose (35%, 23% and 8%, 
respectively). Other errors were underdose, incomplete prescription and duplication 
of therapy. Nitrofurantoin, domperidone & cefixime were common drugs admin-
istered at inappropriate frequency. Drugs involved in overdose were enoxaparin, 
gentamicin, azithromycin & domperidone. The incidence of medication error was 
26%. Antimicrobial agents (34%) had contributed maximum to the error followed 
by GI agents (20%), anticoagulants (11%) and CNS agents (8%). All the errors were 
category B error (NCC MERP medication error index) ConClusions: The avail-
ability of such evidence will help in improving patient safety in Indian setting and 
to promote medication safety.
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objeCtives: Causality assessment is the evaluation of the likelihood that a particu-
lar treatment is the cause of an observed adverse event. The aim of this study was to 
ication, which increased to 53.2% by 5 years. Overall, ADHD drug use was most com-
mon in patients aged 1-5 and 6-12 years whereas antipsychotics were most common 
in adolescents (13-17 years) and young adults (18-25 years). The effects of age group 
on the use of the different drug classes were statistically significant (p< 0.0001). We 
observed significant changes in drug use over time for all psychoactive drug classes 
(either increase or decrease), except for anxiolytics. ConClusions: Psychoactive 
medication use increased over the 5-year period among newly diagnosed ASD peo-
ple, whatever the age group. Optimal use of these medications in the context of 
limited access to other types of support modalities is discussed.
PIH10
PrIOr use Of lOng-ActIng reversIble cOntrAcePtIOn metHOds And 
HeAltH PlAn tyPe PredIcts greAter lIkelIHOOd Of HAvIng An Intended 
PregnAncy
Armstrong M.A.1, Postlethwaite D.1, Darbinian J.1, McCoy M.A.2, Law A.W.2
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objeCtives: The objective of this study was to determine if long-acting reversible 
contraception (LARC) use prior to pregnancy and health plan type were associated 
with greater likelihood of having an intended pregnancy (IP). Methods: Women 
members of the Kaiser Permanente, Northern California (KPNC) integrated health 
plan aged 15-44 years who became pregnant between 1/1/2010 and 12/31/2012 were 
identified from KPNC databases. The last contraceptive method used within 2 years 
preceding pregnancy was determined. Key characteristics were compared among 
women with IPs vs. those with unintended pregnancies (UPs-unwanted or mis-
timed). Logistic regression analyses were conducted to determine if health plan 
type, copays or prior LARC use were predictive of IP, controlling for age, race/ethnic-
ity, marital status, education/income, parity, and select comorbidities. Results: 
Among women included in the study, 27,498 (61%) had IPs and 17,853 (39%) had 
UPs. Higher education (47.9% vs. 17.2%), an income ≥ $60,000 (55.0% vs. 21.0%), 
and already having one child (39.0% vs. 21.3%) were significantly (p< 0.0001) more 
common among women with IPs. In comparison to women with IPs, significantly 
(p< 0.0001) larger proportions of women with UPs were ≤ 24 years old (33.7% vs. 
6.5%), single (39.8% vs. 5.5%), and had evidence of comorbidities (7.72% vs. 7.12%). 
When controlling for key characteristics, women who used LARC methods prior to 
pregnancy vs. women using non-LARC methods were 2.3-fold (p< 0.0001) more likely 
to have an IP. Women with deductible plans with health savings accounts (HSA) vs. 
those with non-deductible plans had greater odds of having an IP (1.16, p= 0.01). 
Upon further stratified analysis, prior use of LARC methods was associated with 
significantly greater likelihoods of having an IP across all evaluated race/ethnicities 
and education/incomes levels. ConClusions: Women KPNC members who used 
LARC methods prior to pregnancy and those who had a HSA were more likely to 
have an IP than an UP.
PIH11
AutIsm PrevAlence In cHIldren AmOng tHe unIted stAtes medIcAId 
POPulAtIOn
Xie L.1, Dysinger A.H.1, Wang L.2, Zhang J.2, Shrestha S.2, Wang Y.1, Baser O.3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA, 
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objeCtives: The current study examined patient age, gender, race, geographic 
variation as well as the prevalence of autism in children using U.S. Medicaid 
data. Methods: A retrospective study was performed among the Medicaid fee-for-
service (FFS) population from January 1, 2008 through December 31, 2009. Children 
under age 17 years and diagnosed with autism were identified using International 
Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis 
code 299.0x. A 2-year period of continuous Medicaid FFS enrollment during the 
study period was required. Disease prevalence was stratified by region, state, age, 
gender and race for all patients, and measured by number and percentage in each 
category. Patients with managed care enrollment in any month of 2008 or 2009 
were excluded from the study. Results: A total of 23,589 children diagnosed with 
autism were analyzed. Children age 6-10 years had the highest autism prevalence 
level (4.59%), followed by those age 11-17 (3.62%) and 0-5 years (1.50%). Prevalence 
results according to race are as follows: Asian (6.33%), White (4.06%), Hispanic (3.29%) 
and Black (2.75%). Autism was more likely to be diagnosed among boys (5.01%) than 
girls (1.62%). Geographic variation analysis showed the highest autism prevalence 
in Idaho (34.06%), followed by Oklahoma (17.14%), Connecticut (14.05%), Minnesota 
(13.44%) and Rhode Island (11.33%). The Southern region of the United States was 
found to have the highest autism prevalence for children under age 17 (4.35%), com-
pared to the Midwest (4.03%), Northeast (3.43%) and West (0.82%). ConClusions: 
Children age 6-10 years had a higher probability of being diagnosed with autism, 
with Asian patients most likely to be diagnosed with autism compared to other 
races. Children residing in the Midwestern region of the United States were shown 
to be at a higher risk for an autism diagnosis.
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PrevAlence Of tAste dysfunctIOn In tHe Adult unIted stAtes 
POPulAtIOn: A study Of tHe nAtIOnAl HeAltH And nutrItIOn 
exAmInAtIOn survey
Hinyard L.J.1, McLaughlin L.2
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objeCtives: There are no current nationally representative estimates on taste 
dysfunction for the US population; the last estimates based on the 1994 National 
Health Interview Study indicated population prevalence reports of taste problems 
of 0.6%. The purpose of this study is to provide current estimates of the preva-
lence of taste dysfunction and identify the relationship between taste dysfunction 
and health perception in the US population. Methods: Data from the 2011-2012 
National Health and Nutrition Examination Survey (NHANES) was used to assess 
the prevalence of self-reported taste dysfunction as assessed by the Taste and Smell 
